爵士制药 JAZZ 深 沪
已收盘 02-06 16:00:00 美东时间
165.50
+2.350
+1.44%
华盛通- 最 高166.62
- 今 开164.16
- 成交量 70.34万股
- 最 低 164.16
- 昨 收 163.15
- 总市值 100.57亿
- 52周最高 182.99
- 市盈率 静 19.14
- 换手率 1.16%
- 52周最低 95.49
- 委 比 -76.50%
- 总股本 6076.51万
- 历史最高 194.73
- 量 比 0.94
- 振 幅 1.51%
- 历史最低 31.87
- 每 手 1
- 风险率 22.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rigel Pharmaceuticals Appoints Michael P. Miller to Board of Directors
Rigel Pharmaceuticals Appoints Michael P. Miller to Board of Directors Rigel Pharmaceuticals Inc. has appointed Michael P. Miller to its Board of Directors. Miller brings over forty years of experience in commercial and leadership roles within the biotechnology and pharmaceutical industries. He has
02-03 21:05
ALX Oncology Data From Phase 1b/2 Clinical Study Of CD47-Inhibitor Evorpacept In Combination With Jazz Pharmaceuticals' ZIIHERA Demonstrates CD47 Expression Is Predictive Of Evorpacept Activity
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced new data from a
01-30 21:18
ALX Oncology Reports CD47 Biomarker Predicts Response to Evorpacept in Advanced HER2-Positive Breast Cancer
ALX Oncology Reports CD47 Biomarker Predicts Response to Evorpacept in Advanced HER2-Positive Breast Cancer ALX Oncology Holdings Inc. has announced new data from a Phase 1b/2 clinical trial evaluating its investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatama
01-30 21:15
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology announced new data from a Phase 1b/2 trial showing that CD47 expression predicts response to evorpacept in HER2-positive metastatic breast cancer patients, consistent with findings from the ASPEN-06 gastric cancer trial. Full biomarker analysis will be presented at an upcoming conference.
01-30 13:15
U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio
U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AGNC Investment, Brown & Brown and Korro Bio, on Thursday. HIGHLIGHTS * AGNC Investment Corp AGNC.O :
01-29 15:54
Zymeworks Announces Participation in Upcoming Investor Conferences
<p>Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company managing licensed healthcare assets and developing novel biotherapeutics, announces its management will participate in four upcoming investor conferences in 2026: Citi’s Virtual Oncology Summit (February 18-19), TD Cowen Conference (March 2 in Boston), Leerink Conference (March 9 in Miami), and Citizens Life Science Conference (March 11 in Miami). The company focuses on improving tr...
01-27 11:00
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $235
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $210 to $235.
01-12 17:46
快讯 | Jazz Pharmaceuticals 任命Thomas Riga为首席商务官
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
01-09 05:05
